Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients

Journal of Hepatology

Volumn 65, Issue 4, 2016, Pages 683-691

  Boyd, Anders ^a   Lacombe, Karine ^b,c   Lavocat, Fabien ^d   Maylin, Sarah ^e,f   Miailhes, Patrick ^g   Lascoux Combe, Caroline ^e   Delaugerre, Constance ^e,f,h   Girard, Pierre Marie ^b,c   Zoulim, Fabien ^d,i  

^a INSTITUT PIERRE LOUIS D EPIDÉMIOLOGIE ET DE SANTÉ PUBLIQUE   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e SAINT LOUIS HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g CROIX ROUSSE HOSPITAL   (France)

^h INSERM   (France)

ⁱ HOSPICES CIVILS DE LYON   (France)

Author keywords

cccDNA; Exponential decay; Hepatitis B virus; Intrahepatic HBV DNA; Nucleoside nucleotide analogue

Indexed keywords

ADEFOVIR; CIRCULAR DNA; COVALENTLY CLOSED CIRCULAR DNA; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; DISEASE ASSOCIATION; DNA DETERMINATION; DNA SYNTHESIS; DRUG EFFECT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COINFECTION; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; TENOFOVIR;

EID: 84991628961     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.05.014     Document Type: Article

References (33)

1. [1] Chen, C.-J., Yang, H.-I., Iloeje, U.H., REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology 49 (2009), S72–S84.
2. [2] C.-F. Chen, W.-C. Lee, Yang, H.-I., Chang, H.-C., Jen, C.-L., Iloeje, U.H., et al. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma. Gastroenterology 141 (2011), 1240–1248 1248.e1–e2.
3. [3] Iloeje, U.H., Yang, H.-I., Jen, C.-L., Su, J., Wang, L.-Y., You, S.-L., et al. Risk and predictors of mortality associated with chronic hepatitis B infection. Clin Gastroenterol Hepatol 5 (2007), 921–931.
4. [4] Gish, R., Jia, J.-D., Locarnini, S., Zoulim, F., Selection of chronic hepatitis B therapy with high barrier to resistance. Lancet Infect Dis 12 (2012), 341–353.
5. [5] Hosaka, T., Suzuki, F., Kobayashi, M., Seko, Y., Kawamura, Y., Sezaki, H., et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology 58 (2013), 98–107.
6. [6] Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I.M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381 (2013), 468–475.
7. [7] Zoulim, F., Locarnini, S., Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 137 (2009), e1–e2.
8. [8] Werle-Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126 (2004), 1750–1758.
9. [9] Wong, D.K.-H., Seto, W.-K., Fung, J., Ip, P., Huang, F.-Y., Lai, C.-L., et al. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency. Clin Gastroenterol Hepatol 11 (2013), 1004–1010 e1.
10. [10] M. Dandri, S. Locarnini, New insight in the pathobiology of hepatitis B virus infection. Gut 61 (2012), i6–i17.
11. [11] Protzer, U., Maini, M.K., Knolle, P.A., Living in the liver: hepatic infections. Nat Rev Immunol 12 (2012), 201–213.
12. [12] Sauce, D., Elbim, C., Appay, V., Monitoring cellular immune markers in HIV infection: from activation to exhaustion. Curr Opin HIV AIDS 8 (2013), 125–131.
13. [13] Iser, D.M., Avihingsanon, A., Wisedopas, N., Thompson, A.J., Boyd, A., Matthews, G.V., et al. Increased intrahepatic apoptosis but reduced immune activation in HIV-HBV co-infected patients with advanced immunosuppression. AIDS 25 (2011), 197–205.
14. [14] Boyd, A., Gozlan, J., Miailhes, P., Lascoux-Combe, C., Cam, M.S.-L., Rougier, H., et al. Rates and determinants of hepatitis B “e” antigen and hepatitis B surface antigen seroclearance during long-term follow-up of patients coinfected with HIV and hepatitis B virus. AIDS 30 (2015), 778–788.
15. [15] Lacombe, K., Boyd, A., Lavocat, F., Pichoud, C., Gozlan, J., Miailhes, P., et al. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients. Hepatology 58 (2013), 912–922.
16. [16] S. Maylin, A. Boyd, Martinot-Peignoux, M., Delaugerre, C., Bagnard, G., Lapalus, M., et al. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus. J Clin Virol 56 (2013), 306–311.
17. [17] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 50 (2009), 227–242.
18. [18] Matthews, G.V., Seaberg, E.C., Avihingsanon, A., Bowden, S., Dore, G.J., Lewin, S.R., et al. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. Clin Infect Dis 56 (2013), e87–e94.
19. [19] Ockenga, J., Tillmann, H.L., Trautwein, C., Stoll, M., Manns, M.P., Schmidt, R.E., Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 (1997), 18–24.
20. [20] Boyd, A., Gozlan, J., Maylin, S., Delaugerre, C., Peytavin, G., Girard, P.-M., et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology 60 (2014), 497–507.
21. [21] Thompson, A.J.V., Nguyen, T., Iser, D., Ayres, A., Jackson, K., Littlejohn, M., et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 51 (2010), 1933–1944.
22. [22] Addison, W.R., Walters, K.-A., Wong, W.W.S., Wilson, J.S., Madej, D., Jewell, L.D., et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 76 (2002), 6356–6363.
23. [23] Zhu, Y., Yamamoto, T., Cullen, J., Saputelli, J., Aldrich, C.E., Miller, D.S., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 75 (2001), 311–322.
24. [24] Nassal, M., HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64 (2015), 1972–1984.
25. [25] Marcellin, P., Gane, E.J., Flisiak, R., Manns, M.P., Kaita, K., Gaggar, A., et al. Evidence for ongoing low-level viremia in patients with chronic hepatitis B receiving long-term nucleos(t)ide analog therapy. Hepatology, 60, 2014, 1093A.
26. [26] Mason, W.S., Xu, C., Low, H.C., Saputelli, J., Aldrich, C.E., Scougall, C., et al. The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir. J Virol 83 (2009), 1778–1789.
27. [27] Nowak, M.A., Bonhoeffer, S., Hill, A.M., Boehme, R., Thomas, H.C., McDade, H., Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A 93 (1996), 4398–4402.
28. [28] Murray, J.M., Goyal, A., In silico single cell dynamics of hepatitis B virus infection and clearance. J Theor Biol 366 (2015), 91–102.
29. [29] Rehermann, B., Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 19 (2013), 859–868.
30. [30] M. Crane, S. Sirivichayakul, Chang, J.J., Avihingsanon, A., Ubolyam, S., Buranapraditkun, S., et al. No increase in hepatitis B virus (HBV)-specific CD8+ T cells in patients with HIV-1-HBV coinfections following HBV-active highly active antiretroviral therapy. J Virol 84 (2010), 2657–2665.
31. [31] Sung, J.J.Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A.Y., Wong, V.W.S., et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128 (2005), 1890–1897.
32. [32] T. Volz, M. Lutgehetmann, Wachtler, P., Jacob, A., Quaas, A., Murray, J.M., et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133 (2007), 843–852.
33. [33] M.B. Zeisel, J. Lucifora, Mason, W.S., Sureau, C., Beck, J., Levrero, M., et al. Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut 64 (2015), 1314–1326.